Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 21, 2022 - Issue 12
Submit an article Journal homepage
1,730
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial

Yoichiro Hashimotoa Department of Neurology, Kumamoto City Hospital, Kumamoto, JapanView further author information
,
Mika Komorib Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, JapanCorrespondence[email protected]
View further author information
,
Yuka Tanjib Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, JapanView further author information
,
Akichika Ozekib Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, JapanView further author information
&
Koichi Hiratac Headache Center, Dokkyo Medical University, Mibu, JapanView further author information
Pages 1495-1503 | Received 16 Feb 2022, Accepted 12 May 2022, Published online: 24 Jun 2022

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.